Abstract
The blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain from the periphery. Therefore, discovery of new modalities allowing for effective delivery of drugs and biomacromolecules to the central nervous system (CNS) is of great need and importance for treatment of neurodegenerative disorders. This manuscript focuses on three relatively new strategies. The first strategy involves inhibition of the drug efflux transporters expressed in BBB by Pluronic® block copolymers, which allows for the increased transport of the substrates of these transporters to the brain. The second strategy involves the design of nanoparticles conjugated with specific ligands that can target receptors in the brain microvasculature and carry the drugs to the brain through the receptor mediated transcytosis. The third strategy involves a rtificial hydrophobiz ation of peptides and proteins that facilitates the delivery of the se pe ptides a nd pr oteins ac r oss BBB. This review discusses the current state, advantages and limitations of each of the three technologies and outlines their future prospects.
Keywords: blood-brain barrier, drug efflux, drug delivery, fatty acylation, nanoge, nanoparticles, pluronic block copolymers, poloxamer.
Current Pharmaceutical Design
Title: New Technologies for Drug Delivery Across the Blood Brain Barrier
Volume: 10 Issue: 12
Author(s): A. V. Kabanov and E. V. Batrakova
Affiliation:
Keywords: blood-brain barrier, drug efflux, drug delivery, fatty acylation, nanoge, nanoparticles, pluronic block copolymers, poloxamer.
Abstract: The blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain from the periphery. Therefore, discovery of new modalities allowing for effective delivery of drugs and biomacromolecules to the central nervous system (CNS) is of great need and importance for treatment of neurodegenerative disorders. This manuscript focuses on three relatively new strategies. The first strategy involves inhibition of the drug efflux transporters expressed in BBB by Pluronic® block copolymers, which allows for the increased transport of the substrates of these transporters to the brain. The second strategy involves the design of nanoparticles conjugated with specific ligands that can target receptors in the brain microvasculature and carry the drugs to the brain through the receptor mediated transcytosis. The third strategy involves a rtificial hydrophobiz ation of peptides and proteins that facilitates the delivery of the se pe ptides a nd pr oteins ac r oss BBB. This review discusses the current state, advantages and limitations of each of the three technologies and outlines their future prospects.
Export Options
About this article
Cite this article as:
Kabanov V. A. and Batrakova V. E., New Technologies for Drug Delivery Across the Blood Brain Barrier, Current Pharmaceutical Design 2004; 10 (12) . https://dx.doi.org/10.2174/1381612043384826
DOI https://dx.doi.org/10.2174/1381612043384826 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress Signaling in Alzheimers Disease
Current Alzheimer Research Axonal Ionic Pathophysiology in Human Peripheral Neuropathy and Motor Neuron Disease
Current Neurovascular Research A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science D1 and Functionally Selective Dopamine Agonists as Neuroprotective Agents in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry <i>Thespesia populnea</i>: An Ethnomedicinal, Phytochemical and Pharmacological Review
The Natural Products Journal Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Recent Patents in Dendrimers for Nanomedicine: Evolution 2014
Recent Patents on Nanomedicine Antioxidants as a Potential Therapy Against Age-Related Neurodegenerative Diseases: Amyloid Beta Toxicity and Alzheimers Disease
Current Pharmaceutical Design Nutraceutical: A Drug, Dietary Supplement and Food Ingredient
Current Pharmacogenomics and Personalized Medicine Insilico Analysis of Post-Translational Modifications in DRD2 Receptor Protein in Schizophrenic Patients
Current Proteomics Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Cannabinoids and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Preface
Current Enzyme Inhibition Statistical Voxel-Based Methods and [18F]FDG PET Brain Imaging: Frontiers for the Diagnosis of AD
Current Alzheimer Research Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Current Medicinal Chemistry Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Somatostatin and Cognitive Function in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Structural Properties of the NMDA Receptor and the Design of Neuroprotective Therapies
Mini-Reviews in Medicinal Chemistry Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis
Current Pharmaceutical Design